2014-10-08 · Notice · 2014-23961
Determination That LUPRON DEPOT (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Leuprolide
Open attributed record →Federal Register publication year
2014 FDA Federal Register peptide records
6 documents attributed to FDA and HHS and published in 2014, connected only through exact reviewed peptide-name matches.
2014-08-20 · Notice · 2014-19713
Determination That LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial and 7.5 Milligrams/Vial; and LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 7.5 Milligrams/Vial and 7.5 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Leuprolide
Open attributed record →2014-08-04 · Notice · 2014-18304
Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting
Liraglutide
Open attributed record →2014-07-23 · Notice · 2014-17293
Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability
Lanreotide
Open attributed record →2014-05-23 · Notice · 2014-11926
Determination of Regulatory Review Period for Purposes of Patent Extension; LINZESS
Linaclotide
Open attributed record →2014-04-02 · Notice · 2014-07330
Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability
Leuprolide + Octreotide
Open attributed record →